Imbria Pharmaceutical FORTITUDE-HCM Clinical Trial Launch (for non-obstructive HCM patients)

Join HCMA CEO and Founder, Lisa Salberg, and her guest, Dr. Marty Maron, to learn more about Imbria Pharmaceutical's FORTITUDE-HCM Clinical Trial Launch for non-obstructive HCM patients. 

What is the study?
The FORTITUDE-HCM study is specifically for the non-obstructed HCM community to address peak oxygen consumption and uptake. The study hypothesizes that it will improve cardiac energetics and symptoms (such as chest pain, shortness of breath, and fainting), thus potentially making you feel better, by allowing your heart to work more efficiently.